IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director Bruce L. Claflin purchased 1,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were purchased at an average cost of $179.58 per share, with a total value of $179,580.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $179,580. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up $3.67 during trading on Friday, hitting $172.95. 726,185 shares of the stock were exchanged, compared to its average volume of 627,783. IDEXX Laboratories, Inc. has a 12 month low of $140.63 and a 12 month high of $198.73. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97. The company has a market cap of $14,764.38, a P/E ratio of 53.57, a PEG ratio of 2.08 and a beta of 0.58.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.77 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.04. The company had revenue of $506.00 million during the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The firm’s quarterly revenue was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.58 EPS. equities analysts predict that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.

A number of brokerages have recently weighed in on IDXX. Piper Jaffray Companies upped their price target on shares of IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Bank of America upped their price target on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. BidaskClub raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, January 31st. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $210.00 price target on shares of IDEXX Laboratories in a report on Monday, January 29th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the stock. IDEXX Laboratories has an average rating of “Buy” and an average target price of $194.00.

A number of hedge funds have recently added to or reduced their stakes in the stock. National Asset Management Inc. increased its position in IDEXX Laboratories by 2.1% during the 2nd quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock worth $332,000 after purchasing an additional 42 shares in the last quarter. QS Investors LLC increased its position in IDEXX Laboratories by 1.5% during the 2nd quarter. QS Investors LLC now owns 4,068 shares of the company’s stock worth $657,000 after purchasing an additional 60 shares in the last quarter. Thrivent Financial For Lutherans increased its position in IDEXX Laboratories by 3.1% during the 2nd quarter. Thrivent Financial For Lutherans now owns 3,340 shares of the company’s stock worth $539,000 after purchasing an additional 100 shares in the last quarter. LS Investment Advisors LLC increased its position in IDEXX Laboratories by 8.2% during the 3rd quarter. LS Investment Advisors LLC now owns 4,846 shares of the company’s stock worth $754,000 after purchasing an additional 368 shares in the last quarter. Finally, Norinchukin Bank The increased its position in IDEXX Laboratories by 6.2% during the 3rd quarter. Norinchukin Bank The now owns 6,495 shares of the company’s stock worth $1,010,000 after purchasing an additional 379 shares in the last quarter. Institutional investors and hedge funds own 86.72% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “IDEXX Laboratories, Inc. (IDXX) Director Buys $179,580.00 in Stock” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/02/10/idexx-laboratories-inc-idxx-director-buys-179580-00-in-stock.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.